Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow margin | (668.0%) | (322.5%) | (110.0%) | 370.8% | 56.9% | (76.7%) | (89.0%) | (106.8%) | (185.8%) | (154.1%) | (345.3%) | (491.7%) | (789.4%) | (541.6%) | (920.5%) | (190.5%) | (139.1%) | (85.0%) | (59.1%) | 2.3% |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Microsoft Corp's last 12-month Free Cash Flow margin is 0.8%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Free Cash Flow margin for Alnylam Pharmaceuticals, Inc. have been (49.4%) over the past three years, and (94.7%) over the past five years.
As of today, Alnylam Pharmaceuticals, Inc.'s Free Cash Flow margin is 0.8%, which is higher than industry median of (753.4%). It indicates that Alnylam Pharmaceuticals, Inc.'s Free Cash Flow margin is Good.